|
Jun 27
|
Theralase(R) Extends Warrants
|
|
May 30
|
TSX Gems: McCoy Global And 2 Other Promising Penny Stocks
|
|
May 30
|
Theralase(R) 1Q2025 Financial Statements
|
|
May 29
|
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
|
|
May 28
|
Theralase to Present Groundbreaking Research at ASTRO 2025
|
|
May 20
|
Theralase Provides Corporate Update
|
|
Apr 14
|
Theralase(R) Closes Non-Brokered Private Placement
|
|
Apr 10
|
TSX Penny Stocks: 3 Picks With Market Caps Under CA$300M
|
|
Apr 10
|
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
|
|
Sep 24
|
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
|
|
Jun 20
|
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
|
|
Jun 19
|
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
|
|
Jun 18
|
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
|
|
Jan 15
|
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
|
|
Dec 4
|
Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA
|
|
Nov 29
|
Theralase Release's 3Q2023 Interim Financial Statements
|
|
Nov 29
|
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
|
|
Oct 23
|
Theralase(R) Announces Brokered LIFE Financing
|
|
Oct 23
|
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
|
|
Sep 7
|
Theralase(R) Closes Private Placement Equity Financing
|